<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02110329</url>
  </required_header>
  <id_info>
    <org_study_id>2007/040/HP</org_study_id>
    <nct_id>NCT02110329</nct_id>
  </id_info>
  <brief_title>Simultaneaous Detection of Quantitative Somatic Alterations Using the Qantitative Multiplex Pcr of Short Fluorescent Fragments Method (QMPSF) in Stage II-III Colon Cancer: a Prospective Study</brief_title>
  <acronym>Code Barre</acronym>
  <official_title>Simultaneous Detection of Somatic Quantitative Molecular Alterations Using the Qantitative Multiplex Pcr of Short Fluorescent Fragments Method (QMPSF) in Stage II-III Colon Cancer: a Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lymph node involvement remains the main criteria for postoperative chemotherapy in patients&#xD;
      with colon cancer (CC) without distant metastasis. To date, the prognostic value of the&#xD;
      somatic quantitative molecular alterations such as loss or gain of genomic region is not&#xD;
      established in CC.&#xD;
&#xD;
      AIMS &amp; METHODS: Using the one-step screening method based on the Quantitative Multiplex PCR&#xD;
      of Short fluorescent Fragments (QMPSF), we aimed to assess the prognostic role of the&#xD;
      simultaneous detection of main quantitative somatic alterations in stage II-III CC.&#xD;
&#xD;
      Patients and Methods. We enrolled and collected all baseline characteristics of patients&#xD;
      operated for a stage II-III CC with storage frozen tissues. The QMPSF was based on a&#xD;
      simultaneous amplification of 9 selected target genomic sequences from literature: DCC&#xD;
      (18q21); EGFR (7p12); P53 (17p13.1); BLK (8p23-p22); c-myc (8q24.12); APC (5q22.2); ERBB2&#xD;
      (17q12); STK6 (20q13.31); NR21 (14p11.1) and two control: DCOHM (5q31.1); HMBS (11q23.3).&#xD;
      Comparison of each amplicon electropherograms obtained from tumour vs normal peritumoral&#xD;
      tissue allowed us to identified gain or loss genomic region. The primary end-point was the&#xD;
      local and/or distant recurrence and relation between clinical and single or combined&#xD;
      molecular alterations and recurrence were evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurence rate according to molecular results</measure>
    <time_frame>36 months</time_frame>
    <description>Using the one-step screening method based on the Quantitative Multiplex PCR of Short fluorescent Fragments (QMPSF), we aimed to assess the prognostic role of the simultaneous detection of main quantitative somatic alterations in stage II-III CC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival rate according to molecular results</measure>
    <time_frame>60 months</time_frame>
    <description>Using the one-step screening method based on the Quantitative Multiplex PCR of Short fluorescent Fragments (QMPSF), we aimed to assess the prognostic role of the simultaneous detection of main quantitative somatic alterations in stage II-III CC.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">401</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Stage II and III</condition>
  <arm_group>
    <arm_group_label>stage II-III colon cancer treated with surgery</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>stage II-III colon cancer treated with surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>evaluation of the recurrence rate according to molecular analysis</intervention_name>
    <arm_group_label>stage II-III colon cancer treated with surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age over 18&#xD;
&#xD;
          -  localized colon cancer&#xD;
&#xD;
          -  proven adenocarcinoma&#xD;
&#xD;
          -  surgery R0&#xD;
&#xD;
          -  no metastatic disease&#xD;
&#xD;
          -  stage II or III&#xD;
&#xD;
          -  WHO performance status 0, 1 or 2&#xD;
&#xD;
          -  availaible frozen tissue&#xD;
&#xD;
          -  written consent&#xD;
&#xD;
          -  no major co-morbidities&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  metastatic disease&#xD;
&#xD;
          -  hereditary colorectal cancer&#xD;
&#xD;
          -  rectal cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chu Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Hopitaux de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>April 7, 2014</study_first_submitted>
  <study_first_submitted_qc>April 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2014</study_first_posted>
  <last_update_submitted>April 7, 2014</last_update_submitted>
  <last_update_submitted_qc>April 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <keyword>stage II and III</keyword>
  <keyword>somatic quantitative molecular alterations</keyword>
  <keyword>Qantitative Multiplex Pcr of Short fluorescent Fragments method (QMPSF)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

